Global DNA methylation levels analysis in a serie of hematological, breast and colorectal cancer samples from Argentina.

MAYORDOMO, ANDREA CONSTANZA; CAJAL, ANDREA; VACCARO, CARLOS; PAVICIC, WALTER; CERLIANI, MARÍA BELÉN; PIÑERO, TAMARA; GARCÍA RIVELLO, HERNÁN; BRAVI, CLAUDIO; SANCHEZ DOVA, ANACLARA; JAUK VITALI, FEDERICO; RICHARD, SILVINA MARIEL

Mar del Plata

Congreso; REUNIÓN ANUAL DE SOCIEDADES DE BIOCIENCIA 2019 - LXIV Reunión Anual de la Sociedad Argentina de Investigación Clínica (SAIC); 2019

SAIC - SAFE - SAB - SAP - NANOMED-ar - AACyTAL

Unlike their normal counterparts, tumor cells exhibit highly variable CpG methylation levels in a large proportion of the genome, which can lead to malignant cell transformation through multiple pathways. This prompted us to assess the extent of LINE1 methylation, a surrogate marker of global DNA methylation, of samples derived from controls and cancer patients from Argentina. Preliminary DNA methylation results from selected samples were replicated in a large serie of 146 controls (blood) and various cancer types: 112 hematological cancer (HemCa), 70 colorectal cancer (CRC) and 68 breast cancer (BrCa) samples. Further, we evaluated correlation with biological, clinical and demographic features. Blood samples were available in all cases, and for solid tumors paired tumoral/non-tumoral adjacent tissues (T/N) were available too. LINE1 methylation level was analyzed by MS-MLPA method. HemCa cases showed statistically significant higher LINE1 methylation level (p